What are MTP inhibitor drugs?

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

MTP inhibitor drugs are pharmacologic agents that share a common mechanism (typically targeting Microsomal triglyceride transfer protein (MTP)). 0 are currently marketed, with 3 more in clinical development.

MTP inhibitor

0 marketed 1 in Phase 3 2 in Phase 2

This page covers all MTP inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Microsomal triglyceride transfer protein (MTP), MTP, HMG-CoA reductase, Microsomal triglyceride transfer protein (MTP) and PPARα.

Targets

Microsomal triglyceride transfer protein (MTP) · MTP, HMG-CoA reductase · Microsomal triglyceride transfer protein (MTP) and PPARα

Phase 3 pipeline (1)

AEGR-733 · Aegerion Pharmaceuticals, Inc. · Cardiovascular / Lipidology
AEGR-733 is a microsomal triglyceride transfer protein (MTP) inhibitor that reduces the production and secretion of apolipoprotein B-containing lipoproteins.

Phase 2 pipeline (2)

AEGR-733 and atorvastatin · Aegerion Pharmaceuticals, Inc. · Cardiovascular
AEGR-733 is a microsomal triglyceride transfer protein (MTP) inhibitor, and atorvastatin is a HMG-CoA reductase inhibitor.
AEGR-733 and fenofibrate · Aegerion Pharmaceuticals, Inc. · Cardiovascular
AEGR-733 is a microsomal triglyceride transfer protein (MTP) inhibitor combined with fenofibrate, a peroxisome proliferator-activated receptor alpha (PPARα) agonist, to reduce triglycerides and apolipoprotein B-containing lipoproteins.

Patent intelligence

mtp inhibitor patent landscape — aggregated cliff calendar, attackable patents, originator estates